Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 40 citing Brandle: Cost effectiveness of statin therapy for the primary prevention of major coronary.... (0.11 sec) 

Platelet activation in type 2 diabetes mellitus


P Ferroni, S Basili, A Falco, G Davi - Journal of Thrombosis and Haemostasis, 2004 - interscience.wiley.com
Summary. The abnormal metabolic state that accompanies diabetes renders arteries
susceptible to atherosclerosis, being capable of altering the functional
properties of multiple cell types, including endothelium and platelets. In ...
Cited by 104 - Related articles - BL Direct - All 3 versions

Disparities in lipid management for African Americans and Caucasians with coronary artery …


MW Massing, KA Foley, L Carter-Edwards, … - BMC Cardiovascular Disorders, 2004 - biomedcentral.com
Individuals with coronary artery disease are at high risk for adverse health
outcomes. This risk can be diminished by aggressive lipid management, but
adherence to lipid management guidelines is far from ideal and substantial ...
Cited by 23 - Related articles - Cached - All 9 versions

Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to …

- rug.nl [PDF] 
J Atthobari, FW Asselbergs, C Boersma, R de … - Clinical therapeutics, 2006 - Elsevier
PREVEND IT was a single-center, double-blind, randomized, placebo-controlled
trial with a 2 × 2 factorial design within the larger observational Prevention
of REnal and Vascular ENdstage Disease (PREVEND) study. The PREVEND IT ...
Cited by 20 - Related articles - All 6 versions

Preventing cardiovascular disease in the 21st century: therapeutic and preventive …

- adisonline.com [PDF] 
ML Daviglus, DM Lloyd-Jones, A Pirzada - American Journal of Cardiovascular Drugs, 2006 - ingentaconnect.com
1 Department of Preventive Medicine, Feinberg School of Medicine, Northwestern
University, Chicago, Illinois, USA 2 Department of Medicine, Division of
Geriatrics, Feinberg School of Medicine, Northwestern University, Chicago, ...
Cited by 18 - Related articles - BL Direct - All 6 versions

A review of the efficacy of rosuvastatin in patients with type 2 diabetes


J Tuomilehto, LA Leiter, D Kallend - International Journal of Clinical Practice, 2004 - interscience.wiley.com
It has been estimated that 92% of individuals with type 2 diabetes, without
cardiovascular disease (CVD), have a dyslipidaemic profile. Several guidelines
on cardiovascular risk now recommend that patients with diabetes should be ...
Cited by 11 - Related articles - BL Direct - All 4 versions

Statin treatment in diabetes mellitus


J Buse - Clinical Diabetes, 2003 - Am Diabetes Assoc
As we mark the tenth anniversary of the publication of the Diabetes Control and
Complications Trial and the fifth anniversary of the United Kingdom Prospective
Diabetes Study, studies which so clearly demonstrate the role of glycemic ...
Cited by 8 - Related articles - All 2 versions

A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful …


PA Scuffham, S Chaplin - Clinical therapeutics, 2005 - Elsevier
The Lescol Intervention Prevention Study (LIPS) was a multinational randomized
controlled trial that showed a 47% reduction in the relative risk of cardiac
death and a 22% reduction in major adverse cardiac events (MACEs) from the ...
Cited by 8 - Related articles - All 6 versions

Review: PROactive 03: Pioglitazone, type 2 diabetes and reducing macrovascular events-- …

- sherbornegibbs.com [PDF] 
J Bottomley, AJ Palmer, R Williams, J … - The British Journal of Diabetes & Vascular Disease, 2006 - dvd.sagepub.com
Page 1. http://dvd.sagepub.com The British Journal of Diabetes & Vascular Disease
DOI: 10.1177/14746514060060020401 2006; 6; 63 British ...
Cited by 6 - Related articles - All 9 versions

Pharmaco-economic issues for diabetes therapy


JM Bottomley, FD Raymond - Best Practice & Research Clinical Endocrinology & …, 2007 - Elsevier
A systematic review was undertaken to analyse pharmaco-economic issues in
diabetes, with evidence selected on the basis of relevance and immediacy.
Pharmaco-economics in diabetes primarily relates to making choices about ...
Cited by 3 - Related articles - All 15 versions

Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention …


GL Plosker, KA Lyseng-Williamson - Pharmacoeconomics, 2007 - ingentaconnect.com
A DIS P HARMACOECONOMIC D RUG E VALUATION 1170-7690/07/0012-1031/$44.95/0 ©
2007 Adis Data Information BV. All rights reserved. ... A Pharmacoeconomic
Review of its Use in the Primary and Secondary Prevention of Cardiovascular ...
Cited by 3 - Related articles - All 5 versions


Result Page: 

1

2

3

4

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google